β-Amyloid 1-40, Human, Control Peptide
466.67 $
For reserch purpose only
Shipping cost plus VAT not included , delivery in 7-14 business days
Catalog No
USB-A2275-75G
Supplier
US Biologicals
Size
100 µg
Product Overview
Product Properties
Target Gene
Product Overview
| Description | Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by progressive loss of memory and cognition in the elderly. One of the most important and initial step involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) releasing short 40, 42 & 43 aa peptides (beta amyloid1-40, 1-42, and 1-43). Polymerization of b-amyloid (Ab) and subsequent neuronal deposit (amyloid) leads to the degeneration of neurons involved in memory and cognition. Ab deposits have also been found to contain 2 additional proteins termed a-synuclein and b-synuclein. The 140 aa a-synucleins is identical with non- Ab component (NACP) of AD. The 134 aa human b-synuclein is homologous to 14kD bovine phosphoneuroprotein 14. Mutations in a-synuclein gene causing a replacement of alanine with a threonine may cause the protein to misfold. Synucleins are primarily expressed in the brain. At least 3 forms: two large (140 aa SYN-1 & 149 aa SYN-2) and a small form (SYN-3, 42 aa) are produced by alternative splicing. A2275-75G is recommended for use as control peptide for antibody A2275-74M. |
| Source Antigen | Human synthetic peptide |
| Reactivity | |
| Cross Reactivity | |
| Applications | |
| Molecular Weight |
Product Properties
| Storage | -20°C |
| Grade | Highly Purified |
| Purity | Highly purified |
| Form | Supplied as a liquid in 0.1M acetic acid. Further dilutions can be made in appropriate buffer. |
| Reactivity Life | 12 months |
| Note | For reserch purpose only |
Target Gene
NA
